Patents by Inventor Xavier O. Jirau Serrano

Xavier O. Jirau Serrano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190194212
    Abstract: The invention relates to new compounds that reduce c-Myc expression and useful for cancer treatment, particularly hematological cancers such as aggressive B- and T-cell lymphomas. The new compounds may be combined with adjunct c-Myc inhibor agents such as a PI3K inhibitor, CK-1 inhibitor, Akt-inhibitor, proteasome inhibitor and/or mTor inhibitor. The c-Myc reducing agent may be provided as a lead-in treatment to reduce or initiate reduction of c-Myc prior to adminstration of the adjunct cancer therapeutic agent. Treatment with a c-Myc reducing agent modulates the disease state of the c-Myc overexpressing cancer making it less malignant and more susceptible to adjunctive cancer therapies.
    Type: Application
    Filed: May 15, 2017
    Publication date: June 27, 2019
    Inventors: Changchun Deng, Mark Lipstein, Owen O'Connor, Donald W. Landry, Xiaoming Xu, Shi-Xian Deng, Xavier O. Jirau Serrano
  • Publication number: 20190070183
    Abstract: The invention relates to the co-administration of select proteasome and PI3K inhibitors is useful for treating c-Myc-overexpressing cancers, particularly hematological cancers such as aggressive B- and T-cell lymphomas. In exemplified embodiments, coadministration of a dual PI3K/CK-1 inhibitor with a proteasome inhibitor synergistically increases cell death of aggressive B- and T-cell lymphomas as well as multiple myeloma over the individual or additive effect of either or both agents. This synergistic effect is associated with the previously unknown inhibition of the kinase casein kinase 1 epsilon (CK-1?) by a PI3K inhibitor, such as TGR-1202. Accordingly, use of PI3K inhibitors that possess CK-1? inhibition in combination with proteasome inhibitors provides a new therapy regime for treating c-Myc-overexpressing cancers, and particularly hematological cancers.
    Type: Application
    Filed: November 4, 2016
    Publication date: March 7, 2019
    Inventors: Changchun Deng, Shi-Xian Deng, Donald W. Landry, Mark Lipstein, Michael Mangone, Owen O'Connor, Xavier O. Jirau Serrano, Luigi Scotto, Xiaoming Xu